LADX 1.25 LadRx Corporation
| Range: | 0.63-3.5 | Vol Avg: | 525 | Last Div: | 0 | Changes: | 0.4 |
| Beta: | 1.5 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Mar 29 1989 | Empoloyees: | 2 | ||
| CUSIP: | CIK: | 0000799698 | ISIN: | US2328287071 | Country: | US | |
| CEO: | Dr. Stephen Snowdy Ph.D. | Website: | https://www.cytrx.com | ||||
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow